+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
G

Actively Recruiting

Researchers are evaluating the safety and disease activity changes of telisotuzumab adizutecan combined with bevacizumab compared to the standard treatment of trifluridine and tipiracil LONSURF plus bevacizumab in adults with refractory metastatic colorectal cancer. This Phase 3 study aims to enroll about 990 participants worldwide to better understand these treatments in this patient group. Participants will be randomly assigned to one of two groups one group will receive intravenous telisotuzumab adizutecan with bevacizumab, while the other group will receive the standard of care, which includes oral trifluridine and tipiracil plus intravenous bevacizumab. Treatment will continue for approximately 36 months. During the study, participants will attend regular visits at approved hospitals or clinics where medical assessments, blood tests, questionnaires, and side effect monitoring will take place. The main outcomes measured include objective response up to 15 months and overall survival up to 36 months, with additional measures such as progression-free survival and duration of response tracked up to 24 months. This ongoing monitoring aims to understand the impact and safety of the treatments over time.

Age: 18Years +All GendersPhase 3
88 locations
D

Actively Recruiting

This research evaluates a new care approach for people living with dementia PlwD and their family caregivers in Germany, where about 1.8 million individuals have dementia. The study aims to test whether a specialized nurse-led care management program, supported by a mobile health app linking caregivers to experts and memory clinics, can help stabilize home care, reduce caregiver burden, and ease neuropsychiatric symptoms compared to usual care. The trial focuses on supporting both members of the caregiving pair, called a dyad, recognizing the high care demands and stress involved. Participants are divided into two groups. The intervention group receives personalized dementia care management for 12 months, tailored to their needs and monitored through the app. This app allows caregivers to communicate with care specialists anytime and provides ongoing data about caregiver health and stress to guide timely support. The control group continues with usual care, without this additional support. The intervention adapts in frequency and intensity based on the caregivers reported burden. During the study, participants will be regularly assessed on how stable their home care situation is, caregiver burden, and neuropsychiatric symptoms in the person with dementia, all measured at 12 months after starting. The research team collects data through the app and other evaluations to monitor health and provide appropriate support. The study is randomized and runs until late 2028, with the goal of improving long-term home care for families affected by dementia.

All AgesAll GendersPhase Not Applicable
12 locations
G

Actively Recruiting

This research aims to create a global registry for mitochondrial disorders to unify previous national registries, allowing worldwide participation and supporting studies on the natural history of these diseases. The project is part of the EU-funded GENOMIT initiative, coordinated by Dr. Holger Prokisch at Technische Universitt Mnchen, and intends to improve the design and execution of clinical trials while promoting the translation of basic research into clinical practice. The study collects data from existing networks such as mitoNET in GermanyAustria and Mitocon in Italy, with the possibility of including other countries. Participants with suspected or confirmed mitochondrial diseases are followed with annual assessments using standardized scales like the Newcastle Mitochondrial Disease Scale for Adults and Children, the Scale for the Assessment and Rating of Ataxia, and measures of disease progression. Participants are monitored over a long period, up to 30 years or until discontinuation or death. Annual evaluations assess disease status and progression. The registry complies with national ethics and data protection rules, managing data access accordingly. This setup aims to support natural history studies and facilitate future clinical trials for mitochondrial disorders worldwide.

All AgesAll Genders
34 locations
P

Actively Recruiting

This research aims to gather detailed data and biomaterials from adults diagnosed with Acute Lymphoblastic Leukemia ALL and related diseases, including certain types of Leukemia and Non-Hodgkins Lymphoma. The registry supports ALL research and quality assurance by collecting information regardless of whether patients participate in clinical trials. The study is observational and involves adults diagnosed and treated under ALL protocols. Participants include adults aged 18 and older with ALL subtypes, other leukemias treated according to ALL protocols, and specific subtypes of Non-Hodgkins Lymphoma treated under B-ALL protocols. The study collects data prospectively on diagnosis, treatment, and outcomes, along with biomaterials related to these conditions. Participants provide information during routine clinical care and follow-up visits for up to 10 years. Data collected includes survival rates, remission status assessed by various methods including PET scans, relapse rates, quality of life questionnaires, and monitoring of toxicities and comorbidities. The study tracks overall survival and other outcomes over long-term follow-up to support research and quality assurance in adult ALL and related diseases.

Age: 18Years +All Genders
147 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of two treatment strategies for patients newly diagnosed with advanced ovarian, peritoneal, or fallopian tube cancer. This international, multicenter, randomized, open Phase III trial compares carboplatinpaclitaxel chemotherapy followed by niraparib alone versus carboplatinpaclitaxel combined with bevacizumab followed by both bevacizumab and niraparib. The study includes patients with high-grade, non-mucinous, non-clear cell epithelial tumors at specific advanced stages who have had surgery or plan chemotherapy with interval debulking surgery. All patients receive an initial cycle of carboplatin and paclitaxel before randomization. After central testing of tumor BRCA status, participants are randomly assigned to one of two arms Arm 1 continues with five more cycles of carboplatin and paclitaxel followed by daily niraparib for up to three years Arm 2 receives five cycles of carboplatin and paclitaxel plus bevacizumab, then maintenance bevacizumab for up to one year alongside daily niraparib for up to three years. This design aims to determine if adding bevacizumab improves outcomes over the standard treatment. Participants undergo frequent assessments including scans and laboratory tests to monitor progression-free survival and other health outcomes. Researchers also evaluate overall survival, time to additional therapies, treatment-related side effects, and quality of life up to several years after enrollment. Patients attend regular visits for treatment, monitoring, and completion of questionnaires, with safety follow-up 30 days after the last dose. The entire observation period can last up to 66 months after the last patient joins the trial.

Age: 18Years +FEMALEPhase 3
65 locations
P

Actively Recruiting

Researchers are investigating the effects of additional chemotherapy treatment after surgery or ablation in patients with metastatic colorectal cancer whose tumor lesions have been definitively treated. This phase III, open-label, randomized, controlled trial aims to compare the effectiveness, quality of life, and safety of mFOLFOXIRImFOLFOX-6 chemotherapy against active follow-up without additional chemotherapy. The study also includes a translational research component to analyze tumor biopsies and blood samples for disease relapse markers. Patients are assigned randomly in a 21 ratio to receive either active chemotherapy mFOLFOXIRI, mFOLFOX6, FOLFIRI, or CAPOX for up to six months or structured follow-up without chemotherapy. Chemotherapy regimens involve intravenous infusions and oral medications administered in cycles every two or three weeks, with a maximum of 12 cycles for most treatments. After treatment or follow-up, participants continue with structured monitoring for up to five years. Participants undergo re-assessments every three months during the first two years, including CT or MRI scans of the thorax and abdomen, blood tests, and quality of life evaluations to detect disease relapse. After two years without relapse, follow-up intervals extend to every six months. The primary outcome measured is progression-free survival at 24 months, with secondary outcomes including overall survival, lesion control, adverse events, and quality of life monitored for up to five years following randomization.

Age: 18Years +All GendersPhase 3
79 locations